Health Care • Biotechnology: Pharmaceutical Preparations
$2.58 ▼ -0.13
(-4.80%)
MKT CAP: $32.4M • VOL: 56.9K
52W L $2 52W H $15
ROARABLE / RQD
D- • 39/100
PIOTROSKI
2 / 9
IXHL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $12.0K | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$23.8M | -$30.0M | -$49.7M |
| Operating Margin % | — | -80.0% | — |
| Net Income (GAAP) | -$46.9M | -$18.5M | -$48.8M |
| EBITDA (Normalized) | -$23.8M | -$29.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$12.5M | -$15.8M | -$10.7M |
| Capital Expenditures (CapEx) | $8.0K | $277.0K | — |
| Free Cash Flow (FCF) | -$12.5M | -$16.1M | -$10.7M |
| FCF Margin % | — | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $68.9M | $2.1M | — |
| Total Debt (Short + Long Term) | — | $2.4M | — |
| Total Stockholders' Equity | $73.4M | $964.0K | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IXHL.